Saturday, May 28, 2016

Roth starts Foundation Healthcare at buy

Roth starts Foundation Healthcare at buy

April 19, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Foundation Healthcare (OTC:FDNH) with a “buy” rating and $6 price target. The stock closed at $3.05 on Monday. “The impetus for our buy rating is the potential of the company’s acquisition of University General Hospital (UGH) in Houston to drive increased EBITDA and EPS,” writes analyst Scott […]

FDA extends Probuphine action date

FDA extends Probuphine action date

February 19, 2016 by · Leave a Comment 

Tweet The FDA has extended its action date to consider approval of a NDA for Probuphine for the maintenance treatment of opioid addiction by the standard period to May 27 from Feb. 27. Following the Psychopharmacologic Advisory Committee meeting in January, which recommended approval of Probuphine, the FDA requested additional changes to the Risk Evaluation […]

Roth ups Titan Pharma price target to $7.25

Roth ups Titan Pharma price target to $7.25

December 4, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target on “buy-rated” Titan Pharmaceuticals (NASDAQ:TTNP) to $7.25 from $6.50 to reflect an increased value attributed to Titan’s pipeline. The stock closed at $4.92 on Thursday. “Key takeaways [following discussions with Titan’s management] include that the Probuphine NDA appears on track, there are no changes to our […]

Roth upgrades ANI Pharma to buy

Roth upgrades ANI Pharma to buy

September 28, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has upgraded ANI Pharmaceuticals (NASDAQ:ANIP) to ”buy” from “neutral” but lowered its price target to $60 from $67. The stock closed at $43.21 on Friday. “We are upgrading shares of ANI Pharmaceuticals … based on a significant reduction in valuation despite sound fundamentals,” writes analyst Scott Henry, adding the reduced price […]

Roth upgrades IGI Labs to buy

Roth upgrades IGI Labs to buy

July 24, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has upgraded IGI Laboratories (NYSE MKT:IG) to “buy” from “neutral” and raised its price target to $11 from $7, saying 2016 could be a breakout year. The stock closed at $6.78 on Thursday. “The impetus for our upgrade is stabilization of the econazole nitrate franchise, a lower valuation, and potential ANDA […]

ROTH ups Titan Pharma price target to $1.50

ROTH ups Titan Pharma price target to $1.50

July 17, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target on Titan Pharmaceuticals (OTCQB:TTNP) to $1.50 from $1.25. The stock closed at 80 cents on Thursday. Analyst Scott Henry writes that the driver for the increased price target is the positive Phase 3 data on Probuphine, which was reported last month. Probuphine is a six-month implant […]

Roth upgrades QLT to buy

Roth upgrades QLT to buy

June 9, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has upgraded QLT (NASDAQ:QLTI; TSX:QLT) to “buy” from “neutral” and raised its price target to $5.50 from $4.50, following the proposed acquisition of InSite Vision (OTC:INSV). The stock closed at $3.99 on Monday. “We believe that QLT’s financial resources could unlock the value in this emerging eye care company,” writes analyst […]

Roth starts Zosano Pharma at buy

Roth starts Zosano Pharma at buy

February 23, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Zosano Pharma (NASDAQ:ZSAN) with a “buy” rating and price target of $20. The stock closed at $11.09 on Friday. Zosano Pharma has a microneedle “patch” platform that provides injection-like results with a more tolerable delivery vehicle. “The impetus for our buy rating is the potential of the […]

Roth starts Titan Pharma at buy

Roth starts Titan Pharma at buy

January 20, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of Titan Pharmaceuticals (OTCBB:TTNP) with a “buy” rating and a price target of $1.25. The stock closed at 47 cents on Monday. “The impetus for our buy rating is the potential of the company’s developmental Probuphine six-month implant of buprenorphine for the treatment of opioid dependence,” writes analyst […]

Roth starts NeuroDerm at buy

Roth starts NeuroDerm at buy

December 9, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of NeuroDerm (NASDAQ:NDRM) with a “buy” rating and $17.50 price target. The stock closed at $8.04 on Monday. “The impetus for our buy rating is the potential of the company’s new treatments for Parkinson’s disease (ND0612H and ND0612L) to improve efficacy and reduce side effects versus the current […]

Next Page »

Email Newsletters with Constant Contact
Google+